Company Filing History:
3 out of 141 
3 out of 28 
2 out of 1,744 
Years Active: 2022-2025
Title: Elise Chiffoleau: Innovator in Immunotherapy
Introduction
Elise Chiffoleau is a prominent inventor based in Nantes, France. She has made significant contributions to the field of immunotherapy, holding three patents that showcase her innovative work. Her research focuses on enhancing T-cell responses and developing specific antibodies for therapeutic applications.
Latest Patents
One of her latest patents is titled "Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof." This invention pertains to immunotherapy and provides specific humanized anti-CLEC-1A antibodies that can bind to the CLEC-1A receptor. These compounds are designed to antagonize the binding of CLEC-1A to its endogenous ligands, offering potential treatments for various deleterious conditions.
Another significant patent is "Method of promoting a T-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)." This invention outlines methods for promoting T-cell responses by examining the expression and function of CLEC-1 in human dendritic cells. The research demonstrated that disruption of CLEC-1 signaling enhances T-cell priming and activation, particularly in Th17 and Th1 cells.
Career Highlights
Elise Chiffoleau has worked with notable organizations such as Université de Nantes and Ose Immunotherapeutics. Her work in these institutions has been pivotal in advancing research in immunotherapy and T-cell modulation.
Collaborations
She has collaborated with esteemed colleagues, including Nicolas Poirier and Bernard Vanhove, contributing to the collective knowledge and advancements in her field.
Conclusion
Elise Chiffoleau's innovative work in immunotherapy and her contributions through her patents highlight her as a leading figure in the scientific community. Her research continues to pave the way for new therapeutic approaches in treating various health conditions.